SINTX Technologies Announces Appointment of Eric K. Olson as Chief Executive Officer
SINTX Technologies (NASDAQ: SINT) has appointed Eric K. Olson as its new Chief Executive Officer and President, succeeding B. Sonny Bal, MD. Dr. Bal will continue as Chairman of the Board. Olson, a serial entrepreneur with over 30 years of experience in medical devices and biomaterials, previously served as CEO during the company's 2014 IPO when it was known as Amedica He most recently founded Foresite Innovations,
The company also designated Gregg Honigblum as Board Advisor. Honigblum, a Managing Director at FNEX Securities, has over 35 years of financial advisory experience and was instrumental in raising SINTX's private equity funding before its IPO. The leadership changes aim to accelerate development and commercialization of SINTX's technologies and enhance shareholder value.
SINTX Technologies (NASDAQ: SINT) ha nominato Eric K. Olson come nuovo Amministratore Delegato e Presidente, succedendo a B. Sonny Bal, MD. Il Dott. Bal continuerà come Presidente del Consiglio. Olson, un imprenditore seriale con oltre 30 anni di esperienza nei dispositivi medici e nei biomateriali, ha precedentemente ricoperto il ruolo di CEO durante l'IPO dell'azienda nel 2014, quando era conosciuta come Amedica. Recentemente ha fondato Foresite Innovations.
La società ha anche designato Gregg Honigblum come Consulente del Consiglio. Honigblum, Direttore Generale di FNEX Securities, ha oltre 35 anni di esperienza nella consulenza finanziaria ed è stato determinante nel raccogliere fondi di private equity per SINTX prima della sua IPO. I cambiamenti nella leadership mirano ad accelerare lo sviluppo e la commercializzazione delle tecnologie di SINTX e a migliorare il valore per gli azionisti.
SINTX Technologies (NASDAQ: SINT) ha nombrado a Eric K. Olson como su nuevo Director Ejecutivo y Presidente, sucediendo a B. Sonny Bal, MD. El Dr. Bal continuará como Presidente de la Junta. Olson, un empresario en serie con más de 30 años de experiencia en dispositivos médicos y biomateriales, anteriormente se desempeñó como CEO durante la OPI de la empresa en 2014, cuando era conocida como Amedica. Recientemente fundó Foresite Innovations.
La compañía también designó a Gregg Honigblum como Asesor de la Junta. Honigblum, Director General en FNEX Securities, cuenta con más de 35 años de experiencia en asesoría financiera y fue fundamental en la recaudación de fondos de capital privado para SINTX antes de su OPI. Los cambios en el liderazgo tienen como objetivo acelerar el desarrollo y la comercialización de las tecnologías de SINTX y mejorar el valor para los accionistas.
SINTX Technologies (NASDAQ: SINT)는 Eric K. Olson을 새 CEO 겸 사장으로 임명하였으며, 이는 B. Sonny Bal, MD의 후임입니다. Bal 박사는 이사회 의장으로 계속 활동할 것입니다. Olson은 의료기기 및 생체 재료 분야에서 30년 이상의 경험을 가진 연쇄 기업가로, 과거에는 Amedica로 알려졌던 회사의 2014년 IPO 기간 동안 CEO로 재직했습니다. 그는 최근 Foresite Innovations를 창립했습니다.
또한 회사는 Gregg Honigblum을 이사회 자문으로 지명했습니다. Honigblum은 FNEX Securities의 전무 이사로 35년 이상의 금융 자문 경험을 보유하고 있으며, SINTX의 IPO 이전에 사모펀드 조달에 중요한 역할을 했습니다. 이러한 리더십 변화는 SINTX 기술의 개발 및 상업화를 가속화하고 주주 가치를 향상시키는 것을 목표로 하고 있습니다.
SINTX Technologies (NASDAQ: SINT) a nommé Eric K. Olson comme nouveau Directeur Général et Président, succédant à B. Sonny Bal, MD. Le Dr Bal continuera en tant que Président du Conseil. Olson, un entrepreneur en série avec plus de 30 ans d'expérience dans les dispositifs médicaux et les biomatériaux, a précédemment été CEO lors de l'introduction en bourse de l'entreprise en 2014, lorsqu'elle était connue sous le nom d'Amedica. Il a récemment fondé Foresite Innovations.
L'entreprise a également désigné Gregg Honigblum comme Conseiller du Conseil. Honigblum, Directeur Général chez FNEX Securities, possède plus de 35 ans d'expérience en conseil financier et a joué un rôle clé dans le financement par capitaux privés de SINTX avant son introduction en bourse. Les changements de direction visent à accélérer le développement et la commercialisation des technologies de SINTX et à améliorer la valeur pour les actionnaires.
SINTX Technologies (NASDAQ: SINT) hat Eric K. Olson zum neuen Geschäftsführer und Präsidenten ernannt, der B. Sonny Bal, MD, nachfolgt. Dr. Bal wird weiterhin Vorsitzender des Boards sein. Olson, ein serieller Unternehmer mit über 30 Jahren Erfahrung in der Medizintechnologie und Biomedizin, war zuvor CEO während des IPO des Unternehmens im Jahr 2014, als es noch Amedica hieß. Zuletzt gründete er Foresite Innovations.
Das Unternehmen hat auch Gregg Honigblum als Board Advisor ernannt. Honigblum, Managing Director bei FNEX Securities, hat über 35 Jahre Erfahrung in der Finanzberatung und war maßgeblich daran beteiligt, SINTXs Private-Equity-Finanzierung vor dem IPO zu beschaffen. Die Änderungen in der Führung zielen darauf ab, die Entwicklung und Kommerzialisierung der Technologien von SINTX zu beschleunigen und den Wert für die Aktionäre zu steigern.
- Appointment of experienced CEO with prior knowledge of the company
- Retention of former CEO as Chairman of the Board for continuity
- Addition of experienced financial advisor to the Board
- Potential disruption due to leadership change
- Uncertainty regarding new CEO's strategy and its impact on ongoing projects
Salt Lake City, Utah., Aug. 06, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”) today announced that its Board of Directors has appointed Eric K. Olson to succeed B. Sonny Bal, MD as the Company’s Chief Executive Officer and President.
Mr. Olson’s appointment follows the Company’s recent announcement that Dr. Bal was retiring from his position as Chief Executive Officer and President effective upon the appointment of a new chief executive officer and president by the Board of Directors. Dr. Bal will continue to serve as Chairman of the Board on the Company’s Board of Directors.
For over 30 years, Mr. Olson has been a serial founder and entrepreneur in a broad range of medical device, diagnostic, biologic and biomaterial companies. Most recently Mr. Olson was the Founder, Chief Executive Officer and Board Member of Foresite Innovations, LLC, a private healthcare innovation and development holding company. He is accomplished in leading and motivating all levels of management in a variety of company sizes and industries both domestically and internationally. Mr. Olson previously served as CEO, President, and as a member of the Board of Directors for the Company while it was known as “Amedica Corporation.” Mr. Olson played a key role in the Company’s 2014 initial public offering and becoming listed on the NASDAQ Capital Market. Mr. Olson has served in senior executive roles of President, Chief Executive Officer and as a member of the Board Directors.
“On behalf of SINTX’s board, I am extremely excited that Eric has agreed to serve as our next CEO and President,” said Dr Bal. “Eric brings many years of experience and leadership qualities that will be crucial in guiding the Company in the coming years.”
“We remain focused on accelerating development and commercialization of the Company’s technologies and looking for new opportunities that will enhance shareholder value,” stated Mr. Olson.
The SINTX Board of Directors also designated Gregg Honigblum as Board Advisor. Mr. Honigblum has over 35 years’ experience as a financial advisor and is a Managing Director for FNEX Securities (https://fnex.com/people/gregg-honigblum/). From 2003 to 2013, Mr. Honigblum was responsible for raising the Company’s private equity funding prior to its IPO in 2014. From, 2006 to 2013, Mr. Honigblum was a member of the Board of Directors of SINTX Technologies (formerly Amedica Corporation).
About SINTX Technologies, Inc.
SINTX Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Over the past several years, SINTX has utilized strategic acquisitions and alliances to enter into new markets. The Company has manufacturing and R&D facilities in Utah and Maryland.
For more information on SINTX Technologies or its materials platform, visit www.sintx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”) that are subject to a number of risks and uncertainties. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. A discussion of risks and uncertainties can be found in SINTX’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the SEC on March 27, 2024, and in SINTX’s other filings with the SEC. SINTX disclaims any obligation to update any forward-looking statements. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report.
Business and Media Inquiries for SINTX:
SINTX Technologies
801.839.3502
IR@sintx.com
FAQ
Who is the new CEO of SINTX Technologies (SINT)?
What is Eric K. Olson's background before joining SINTX Technologies (SINT)?
What role will former CEO B. Sonny Bal have at SINTX Technologies (SINT)?
Who has been designated as Board Advisor for SINTX Technologies (SINT)?
